SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sigma Labs, Inc. (SASI) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($2.00, 51.8%).
- Analyst consensus target $2.00 (-51.8% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 17/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
17/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SASI
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio17.38
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.45
Book Value / Share$0.00
Revenue / Share$0.24
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$2.00 (-51.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-108.94 |
$1.23M |
$-1.7M |
-137.4% |
| 2016 |
$-140.60 |
$966.42K |
$-2.2M |
-227.3% |
| 2017 |
$-207.91 |
$641.05K |
$-4.58M |
-714.1% |
| 2018 |
$-161.62 |
$388.57K |
$-5.57M |
-1434.5% |
| 2019 |
$-107.76 |
$402.45K |
$-6.34M |
-1574.8% |
| 2020 |
$-29.12 |
$807.49K |
$-5.58M |
-690.5% |
| 2021 |
$-17.27 |
$1.65M |
$-8.49M |
-513.9% |
| 2022 |
$-16.44 |
$630.43K |
$-8.63M |
-1368.7% |
| 2024 |
$-2.23 |
$501.42K |
$-10.12M |
-2018.3% |
| 2025 |
$-1.45 |
$2.14M |
$-10.69M |
-499.5% |
